Living Cell Technologies Ltd., of Sydney, completed treatment of all six patients in group two of the phase IIb trial of Ntcell for Parkinson's disease. Four patients had 80 Ntcell microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no Ntcell implanted. To date, there are no safety issues in any of the six patients. The first five patients in the group were treated between Nov. 12 and 19.